IBCs provide on-site scrutiny of low-risk contained dealings that do not require case-by-case consideration by the Regulator through independent assessment of NLRD proposals pursuant to regulation 13B – and on behalf of their organisation ensuring compliance with legislative requirements. IBCs are required to comprise a range of suitable experts and an independent person.
More information about the role and formation of IBCs can be found in the Explanatory Information on the Guidelines for Accreditation of Organisations and the Guidelines themselves.
What are Notifiable Low Risk Dealings (NLRDs)?
NLRD Documents and Forms
Frequently Asked Questions – Accreditation, Institutional Biosafety Committees (IBCs) & Notifiable Low Risk Dealings (NLRDs)
Guidance for IBCs: Regulatory requirements for contained research with GMOs containing engineered gene drives (PDF 237 KB)
Guidance for IBCs: Regulatory requirements for contained research with GMOs containing engineered gene drives (DOCX 54 KB)
- Note: The above guidance was updated in September 2019 to reflect changes to licensable dealing categories introduced by the Gene Technology Amendment (2019 Measures No. 1) Regulations 2019, commencing on 8 October 2019. For further information on these amendments, see the Amendment Regulation Implementation page.
Requirements under the Gene Technology Act 2000 for clinical trials in humans involving GMOs –Guidance for clinical trial sponsors